David Miles Meredith, M.D.,Ph.D.
Co-Author
This page shows the publications co-authored by David Meredith and Sanda Alexandrescu.
Connection Strength
2.430
-
Embryonal and non-meningothelial mesenchymal tumors of the central nervous system - Advances in diagnosis and prognostication. Brain Pathol. 2022 Mar 09; e13059.
Score: 0.991
-
Molecular Alterations in Pediatric Low-Grade Gliomas That Led to Death. J Neuropathol Exp Neurol. 2021 11 19; 80(11):1052–1059.
Score: 0.240
-
IDH-mutant gliomas with additional class-defining molecular events. Mod Pathol. 2021 07; 34(7):1236-1244.
Score: 0.232
-
Loss of histone H3 trimethylation on lysine 27 and nuclear expression of transducin-like enhancer 1 in primary intracranial sarcoma, DICER1-mutant. Histopathology. 2021 Jan; 78(2):265-275.
Score: 0.226
-
Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Acta Neuropathol Commun. 2020 07 14; 8(1):107.
Score: 0.221
-
Characterization of molecular signatures of supratentorial ependymomas. Mod Pathol. 2020 01; 33(1):47-56.
Score: 0.207
-
Recurrent EP300-BCOR Fusions in Pediatric Gliomas With Distinct Clinicopathologic Features. J Neuropathol Exp Neurol. 2019 04 01; 78(4):305-314.
Score: 0.202
-
Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. Mod Pathol. 2021 02; 34(2):264-279.
Score: 0.056
-
Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523.
Score: 0.054
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.